Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Comparison between trabeculectomy with mitomycin C and Ex-PRESS shunt implantation in uveitis-related glaucoma patients

Poster Details

First Author: A. El Habbak EGYPT

Co Author(s):    M. El Naggar   M. Abd El Zaher   H. El Shiwy   A. Howaidy   A. Falougy        

Abstract Details


The aim of this work is to compare the efficacy of EX-PRESS shunt implantation versus trabeculectomy augmented with mitomycin C (MMC) in patient with Uveitic glaucoma.


Benha University hospital, Ophthalmology Department, Egypt


20 eyes of 20 patients diagnosed with elevated IOP related to uveitis and unsatisfactory medical control of IOP were divided into 2 equal groups. 10 eyes were offered EX-PRESS shunt implantation (P-50 model) and 10 eyes had trabeculectomy augmented with Mitomycin C (MMC). Pre and Postoperative IOP and UCVA were measured and compared during week 1 and after 3 months.


The mean preoperative UCVA was 0.58 in EX-PRESS shunt subgroup, 0.6 in trabeculectomy MMC subgroup. The mean preoperative IOP was 38.2 & 36.7 mmHg respectively. At the first week: The mean postoperative UCVA was 0.6 in the first group and 0.58 in the second group. The mean postoperative IOP in the first week was -16.5 & 14.9 mmHg respectively. In the 3 months follow up visit the mean for the postoperative UCVA was 0.6 & 0.5 for each subgroup respectively. The mean postoperative IOP was 15 & 18 respectively. The average change of IOP in the EX-PRESS shunt group 23.2mmHg at three months, and in trabeculectomy MMC group was 18.7mmHgat three months.


From our results, it is evident that EX-PRESS shunt implantation is safe and effective method for treating Uveitic Glaucoma. However, early hypotony may occur after surgery. Trabeculectomy MMC is also proven to be effective but with higher incidence of complications, frequent need for subsequent interventions or additive drugs to control IOP in Uveitic glaucoma patients.

Financial Disclosure:


Back to Poster listing